We value your privacy

This website or its third-party tools process personal data. You can opt out of the sale of your personal information by clicking on the “Do Not Sell or Share My Personal Information” link.

Powered by

Anoro Ellipta

ACNU Feasibility

View full report
GoodAnoro Ellipta, an inhaled anticholinergic and beta-2 agonist, has moderate side effects and interaction risks, requires proper inhaler technique, regular monitoring, and caution in special populations, with low misuse potential and generally good adherence due to once-daily dosing.

ACNU Feasibility Scorecard

Chart with 11 data points.
Anoro Ellipta
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 1 to 6.
End of interactive chart.